Kamada Plans Three More Biosimilar Launches In Israel
Post Approval, Company Expects Sales Of $5m-$7m From The Candidates
Israeli firm Kamada has entered into two agreements for commercialization of three biosimilars in Israel. The company expects to launch the products between 2022 and 2024.
